Efficacy and safety of adalimumab (HUMIRA®) in 899 patients with rheumatoid arthritis (RA) who previously failed etanercept and/or infliximab in clinical practice

被引：0
|
作者：
Bombardieri, S.
McKenna, F.
Drosos, A. A.
Michel, B. A.
Hartz, D.
Oezer, U.
Kupper, H.
机构：
[1] Univ Pisa, Pisa, Italy
[2] Trafford Gen Hosp, Manchester, Lancs, England
[3] Univ Ioannina, Ioannina, Greece
[4] Univ Zurich, Zurich, Switzerland
[5] Abboth GmbH & Co KG, Ludwigshafen, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [1] Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed infliximab treatment
    Van der Biji, AE
    Breedveld, FC
    Antoni, CE
    Kalden, JR
    Kary, S
    Burmester, GR
    Unnebrink, K
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 428 - +
  • [2] Adalimumab (HUMIRA®) is effective in treating patients with rheumatoid arthritis who previously failed etanercept and/or infliximab in real-life clinical settings.
    Bombardieri, S
    Tzioufas, AG
    McKenna, F
    Özer, Ü
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S144 - S144
  • [3] One-year efficacy of etanercept in rheumatoid arthritis patients who previously failed to infliximab.
    Gómez-Puerta, JA
    Rodriguez-Cros, J
    Graell, E
    Canete, JD
    Albaladejo, C
    Sanmartí, R
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S190 - S190
  • [4] Efficacy and safety of adalimumab (Humira®) as the second or third TNF antagonist used to treat patients with active rheumatoid arthritis (RA) in clinical practice.
    Bombardieri, S.
    Drosos, A. A.
    Malaise, M. G.
    Oezer, U.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S411 - S411
  • [5] Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients
    Brocq, O
    Albert, C
    Roux, C
    Gerard, D
    Breuil, V
    Ziegler, LE
    JOINT BONE SPINE, 2004, 71 (06) : 601 - 603
  • [6] Meta-analysis of the Efficacy and Safety of Adalimumab, Etanercept, and Infliximab for the Treatment of Rheumatoid Arthritis
    Wiens, Astrid
    Venson, Rafael
    Correr, Cassyano J.
    Otuki, Michel Fleith
    Pontarolo, Roberto
    PHARMACOTHERAPY, 2010, 30 (04): : 339 - 353
  • [7] Workplace impacts of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA)
    Birnbaum, Howard
    Pike, Crystal
    Kaufman, Rebecca
    Schiller, Matthew
    Shi, Lizheng
    Sun, Peter
    Ray, Saurabh
    Cifaldi, Mary
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S459 - S459
  • [8] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [9] Safety and efficacy of adalimumab (Humira®) in patients with rheumatoid arthritis in Germany:: React study
    Burmester, GR
    Alten, R
    Tony, H
    Liman, W
    Gromnica-Ihle, E
    Stierle, HE
    Zeidler, H
    Von Hinüber, U
    Kellner, H
    Häntzschel, H
    Lemma, E
    Zeise, E
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 266 - 266
  • [10] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 40 - 40
12345